scout
|Articles|July 10, 2015

Special Reports

  • Gastrointestinal Cancers (Issue 5)
  • Volume 4
  • Issue 2

Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME